Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.55 |
| ▸ | CA2 | P00918 | 4/20 | 0.55 |
| ▸ | CA9 | Q16790 | 4/20 | 0.55 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.51 |
| ▸ | HK1 | P19367 | 2/20 | 0.46 |
| ▸ | HK2 | P52789 | 2/20 | 0.46 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23488670 | 0.89 | CA2 (0.54) | CA1CA2CA9LGALS3HK1 | |
| SCHEMBL23488332 | 0.89 | CA2 (0.54) | CA1CA2CA9LGALS3HK1 | |
| SCHEMBL23488325 | 0.89 | CA2 (0.49) | CA1CA2CA9LGALS3HK1 | |
| SCHEMBL23488534 | 0.87 | CA2 (0.50) | CA1CA2CA9LGALS3HK1 | |
| SCHEMBL23488456 | 0.87 | CA2 (0.47) | CA1CA2CA9LGALS3LGALS8 | |
| SCHEMBL23488180 | 0.86 | LGALS3 (0.44) | CA1CA2CA9LGALS3MEN1 | |
| SCHEMBL23488781 | 0.84 | CA2 (0.52) | CA1CA2CA9LGALS3HK1 | |
| SCHEMBL23488440 | 0.84 | CA2 (0.52) | CA1CA2CA9LGALS3HK1 | |
| SCHEMBL23488497 | 0.83 | LGALS8 (0.48) | LGALS3LGALS8MRGPRX4 | |
| SCHEMBL23488312 | 0.81 | CA2 (0.47) | CA1CA2CA9LGALS3LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210170033-A1 | NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210170033-A1 | NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | GPR119, SLC2A8, SLC2A4 | CA1 2052/4885CA2 1099/4885CA9 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.